Baltic bio fusion - Company finances
|
EUR
|
2024
From: 2024-02-22
To: 2024-12-31
|
2025
From: 2025-03-01
To: 2026-02-28
|
|---|---|---|
|
Financial data
|
||
| Sales revenue | 5,021 | 5,168 |
| Profit before tax | -4,037 | -3,592 |
| Net profit | -4,037 | -3,592 |
| Equity | 563 | 782 |
| Liabilities | 0 | 0 |
| Non-current assets | 0 | 0 |
| Current assets | 563 | 782 |
| Total assets | 563 | 782 |
|
Financial indicators
|
||
| Revenue change y/y | - | +2.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -717.1% | -459.3% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -717.1% | -459.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -80.4% | -69.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -80.4% | -69.5% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Baltic bio fusion - Social security debts
The company had no debts to Sodra
Baltic bio fusion - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Baltic bio fusion, MB (code 306686071) is a Small partnership operating in Other technical testing and analysis. In the latest financial year, 2025, the company generated revenue of €5.2K, up 2.9% from €5.0K in 2024. Net profit remained negative at €-3.6K, but the loss narrowed from €-4.0K a year earlier, indicating a modest improvement in operating performance. The profit margin in 2025 stood at -69.5%, showing that the business is still running at a significant loss relative to sales. Over the two-year period, revenue increased slightly while losses decreased, suggesting gradual progress rather than a strong turnaround. The balance sheet remains very small: total assets were €782 and equity was also €782 at the end of 2025. Asset turnover was 6.61x, reflecting revenue generation against a limited asset base. ROE and ROA are negative and should be viewed in the context of the very small equity and asset base.